Ozempic, Rybelsus, and Wegovy (semaglutide) Introduction Ozempic, Rybelsus and Wegovy are products based on the active ingredient and GLP-1 receptor agonist, semaglutide, as developed and marketed by Novo Nordisk
PlexusDx providers can customize your titration schedule and starting dose based on your health history, significantly reducing headache risk during the adjustment phase
Discreet delivery, straight to your door
Mechanisms deciphered in these studies indicate that the interaction between serotonin and GLP-1 in the hindbrain increases proopiomelanocortin/cocaine- and amphetamine-regulated transcript (POMC/CART) neuron activity, leading to induction of satiety signals and suppression of neuropeptide Y/agouti-related peptide (NPY/AgRP) neuron activity, which in turn suppresses hunger
Post-marketing reports of sudden vision loss have occurred with phosphodiesterase inhibitors
What actually happens after each session